Research Topic · Peer-Reviewed

Amphotericin

Amphotericin B is a polyene macrolide antifungal antibiotic, originally derived from Streptomyces bacteria, used to treat serious systemic fungal infections including candidiasis, aspergillosis, cryptococcosis, histoplasmosis, and mucormycosis. It exerts fungicidal activity by binding ergosterol, the dominant sterol…

Curated from this journal's research 📚 6 peer-reviewed articles cited Cited 58× across the literature 🔖 ISSN 2766-869X 🗓 Reviewed July 2026

Overview

Amphotericin B is a polyene macrolide antifungal antibiotic, originally derived from Streptomyces bacteria, used to treat serious systemic fungal infections including candidiasis, aspergillosis, cryptococcosis, histoplasmosis, and mucormycosis. It exerts fungicidal activity by binding ergosterol, the dominant sterol of the fungal plasma membrane, and forming pore-like channels that disrupt membrane integrity. The resulting loss of selective permeability allows efflux of potassium and other essential intracellular components, leading to fungal cell death; an additional oxidative mechanism may contribute. Its preferential binding to fungal ergosterol over mammalian cholesterol underlies selectivity, yet residual interaction with host membranes causes characteristic toxicity, particularly nephrotoxicity, electrolyte loss, and infusion-related reactions. Lipid and liposomal formulations were developed to reduce these effects and enable higher, more effective dosing. The broad antifungal spectrum and fungicidal action of amphotericin B make it a mainstay for aggressive and refractory mycoses, including the angioinvasive moulds of the order Mucorales responsible for mucormycosis, where prompt antifungal therapy is combined with surgical debridement and correction of predisposing conditions. Its mechanism remains a benchmark for evaluating newer agents and natural antifungal compounds, and it informs studies of resistance and combination therapy. Amphotericin B continues to be a cornerstone of treatment for invasive and opportunistic fungal disease, especially in immunocompromised patients.

Research published in this journal

6 peer-reviewed articles, ranked by relevance. Each links to its DOI.

How this research is being cited

The 6 articles above have been cited 58 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.

A sample of recent works citing this journal's research on Amphotericin, linking to each citing work.

Editorial oversight

Curated from peer-reviewed research published in Fungal Diversity (ISSN 2766-869X).

Journal editorial board
Sudha Chaturvedi · United States

This page summarises published research for orientation; it is not medical or professional advice.